Table 4.
Treatment history of patients with PsA (N = 153)
| Characteristics | Patients with PsA (N = 153) |
|---|---|
| Received secukinumab as first treatment, n (%) | 9 (5.9) |
| Received treatment prior to secukinumab, n (%) | 144 (94.1) |
| Treatments received at any time prior to secukinumaba,b | |
| Mean (SD) | 2.7 (1.8) |
| 1, n (%) | 31 (21.5) |
| 2, n (%) | 42 (29.2) |
| ≥ 3, n (%) | 71 (49.3) |
| Any biologics, n (%) | 115 (79.9) |
| Mean (SD) | 1.2 (1.0) |
| 1, n (%) | 65 (45.1) |
| 2, n (%) | 35 (24.3) |
| ≥ 3, n (%) | 15 (10.4) |
| Conventional synthetic DMARDs, n (%) | 101 (70.1) |
| NSAIDs, n (%) | 66 (45.8) |
| Targeted synthetic DMARDs (apremilast), n (%) | 14 (9.7) |
| Treatments directly preceding secukinumab, n (%)a,b | |
| Any biologics | 94 (65.3) |
| Conventional synthetic DMARDs | 62 (43.1) |
| NSAIDs | 48 (33.3) |
| Targeted synthetic DMARDs (apremilast) | 7 (4.9) |
DMARD disease-modifying antirheumatic drug; NSAID nonsteroidal anti-inflammatory drug; PsA psoriatic arthritis; SD standard deviation
aAmong patients who had received ≥ 1 treatment prior to secukinumab (n = 144). The number of all previous distinct treatments was considered, regardless of treatment combinations
bMultiple treatments directly preceding secukinumab could be selected for each patient